Key facts
- This page summarizes Daniel Gruskin's Form 4 filing for LogicBio Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2021, 18:31.
Daniel Gruskin - 06 Aug 2021 Form 4 Insider Report for LogicBio Therapeutics, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 06 Aug 2021
- Net transaction value
- -$6,381
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2021, 18:31:22 UTC
- Prior SEC filing
- 20 May 2021
- Next SEC filing
- 03 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Quick, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Gruskin filed Form 4 for LogicBio Therapeutics, Inc. on 10 Aug 2021.
Change
- Previous filing in this sequence was filed on 20 May 2021.
- Current net transaction value: -$6,381.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LOGC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,798
- Change %
- Price
- Shares after
- 4,798
- Date
- 06 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
LOGC
transaction
Common Stock
Sale
- Transaction value
- $6,381
- Shares
- -1,467
- Change %
- -31%
- Price
- $4.35
- Shares after
- 3,331
- Date
- 09 Aug 2021
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LOGC
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,798
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,798
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
Footnote F2
This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above.
Footnote F3
These RSUs vested on August 6, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.